In the latest market close, Medtronic (MDT) reached $85.40, with a +0.18% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 1.83%. Meanwhile, the Dow gained 1.65%, ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Short interest in healthcare stocks in S&P 500 rose slightly in December, with Moderna being the most shorted stock.

Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

The Centers for Medicare & Medicaid Services will review a potential national Medicare coverage policy for renal denervation ...

On Monday, the Centers for Medicare & Medicaid Services (CMS) initiated a national coverage analysis of renal denervation for the treatment of uncontrolled hypertension.

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, ...

TD Cowen analyst Josh Jennings maintained a Buy rating on Medtronic (MDT – Research Report) today and set a price target of $95.00. The ...

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price target of ...